

INAUGURAL MEETING OF THE LUPUS ACADEMY: DRAFT PROGRAMME

FRIDAY 16 MARCH

18:30 Opening address David Isenberg & Ricard Cervera

Keynote Presentation

Moderator: David Isenberg

18:40 Re-classifying lupus: can we improve the ACR

revised criteria and is this a single disease anyway?

Michelle Petri

19:10 Welcome Dinner

SATURDAY 17 MARCH

Plenary

Moderator: Ricard Cervera

08:00 The pathogenesis of lupus: a guide to the perplexed Claudia Mauri

08:20 New biomarkers in lupus: is anything looking really Matthias Schneider

good?

Roundtable: The Kidney

Moderator: David D'Cruz

08:40 Can we really avoid end stage disease in all Elizabeth Lightstone

patients?

09:00 How to identify membranous nephritis before the biopsy and how to approach it?

09:20 Renal microangiopathy related to APS in lupus: how

important is it?

09:40 Questions and Answers

10:10 Coffee

Plenary

Moderator: Roger A. Levy

10:40 The challenge of APS Munther Khamashta

Case Study Workshops

CNS and CV diseases: can we predict? how to
avoid?

John Hanly, Ian Bruce &
David D'Cruz

Pregnancy, contraception and APS: counselling and approach
Imad Uthman, Roger A. Levy & Munther Khamashta

Metrics (BILAG, SLEDAI, SLICC...): how to incorporate into the daily practice
Sandra Navarra, Matthias Schneider & David Isenberg

Maria G. Tektonidou

12:30 Lunch

Roundtable: CV. CNS and Pregnancy

riounatable or, ene and riognamy			
	Moderator: Munther Khamashta		
14:00	Cardiovascular morbidity in SLE: how can we assess	Ian Bruce	
	it?		
14:20	Instruments to measure and outcomes of	John Hanly	
	neuropsychiatric manifestations	•	
14:40	The paradigm of pregnancy in SLE revisited	Roger A. Levy	
12123		- 3 7	
15:00	Questions and Answers		

Case Study Workshops

15:30 Kidney disease: when to biopsy? how to approach? Elizabeth Lightstone, Maria G. Tektonidou & Ricard Cervera

CNS and CV diseases: can we predict? how to John Hanly, Ian Bruce & David D'Cruz avoid?

Pregnancy, contraception and APS: counselling and Imad Uthman, Roger A. Levy & Munther approach Khamashta

Metrics (BILAG, SLEDAI, SLICC...): how to incorporate into the daily practice
Sandra Navarra, Matthias Schneider & David Isenberg

17:00 Close of day 1

SUNDAY 18 MARCH

Roundtable: Treatment I

Moderator: David Isenberg

08:30 What trials on new biologic therapies have taught us? Richard Furie

08:50 Differential drug effects in various ethnic groups? - Sandra Navarra
what are the data?

09:10 The pros and cons of hydroxychloroquine" still life in the old dog yet"!

Guillermo Ruiz-Irastorza

10:00 Coffee

Questions and Answers

Moderator: Sandra Navarra

09:30

Roundtable: Treatment II

12:00	Closing remarks	Ricard Cervera & Roger A. Levy
11:30	Questions and Answers	
11:10	Biologic therapies for lupus – new, shiny and expensive, but do they really work?	David Isenberg
10:50	Lupus needs treating early and aggressively – or not?	David D'Cruz
10:30	Classic and modern immunosuppressive drugs: From the NIH to the Euro-lupus regime	Ricard Cervera

This medical education activity is provided by the European CME Forum on behalf of the Lupus Academy Consortium



This meeting has been independently developed by the Lupus Academy Steering Committee.

CME accreditation will be sought from the appropriate authorities. More information will be available in early 2012.

The Lupus Academy is supported by an educational grant from GlaxoSmithKline and Human Genome Sciences.



